Skip to main content

Affimed N.V. (AFMD)

New York Stock Exchange Healthcare BiotechnologyView data quality →
38.6Poor

ValueMarkers Composite Index

Top 4%#43,098 of 44,714

DCF data not available

Piotroski
0/9
Weak
Beneish
5.00
High Risk
Altman
-10.50
Distress
DCF Value
-
N/A
ROIC
-137.4%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Affimed N.V. (AFMD) — VMCI valuation read

Affimed N.V. (AFMD) carries a VMCI composite of 39/100, 11 points below the Healthcare sector median of 50. Among mid-cap names, that gap places AFMD in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The AFMD insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads AFMD trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 3.2x is the binding constraint on the bear case, the line to track on Affimed N.V.'s next 10-Q.

AFMD held flat 0.0% over the trailing 7 days, with a -3.0% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in AFMD’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.